Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.

Worcester, MA
Rare Disease Day highlights a global challenge: 300+ million people are affected by rare diseases, many with limited or no treatment options.
1
3
99
At Mustang Bio, we’re advancing innovative therapies for devastating conditions, including glioblastoma, an aggressive and rare brain cancer with significant unmet need.
1
69
On Rare Disease Day, we are proud to be a part of the global rare disease community and remain driven by one goal: progress for patients. #RareDiseaseDay #Glioblastoma #MustangBio
57
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma $MBIO $FBIO bit.ly/40BOOzp
7
762
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy $MBIO $FBIO bit.ly/4b5bLNd
7
4
13
2,782
Mustang Bio announces expansion into #autoimmunediseases with MB-106, a CD20-targeted autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the 4th quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more: bit.ly/4azqUGS
2
7
2,019
#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. bit.ly/3Ij0flf #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO
2
707
#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease.
1
2
500
This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: bit.ly/49Ku9KW #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO
512
#DYK X-Linked Severe Combined Immunodeficiency (XSCID), also commonly known as #BubbleBoyDisease, is a rare mutation in the interleukin 2 receptor gamma (IL2RG) gene that makes a newborn immunocompromised?
1
365
There are about 30-40 new patients per year in the U.S. who are diagnosed with the disease and without treatment, most patients do not live past the age of one.
1
274
This #RareDiseaseDay, learn more Mustang Bio’s MB-117 and MB-217 gene therapies to treat XSCID here: bit.ly/49Ku9KW #XSCID #BubbleBoyDisease $MBIO
379
#DYK recurrent glioblastoma (GBM) is a rare and aggressive #braincancer that impacts approximately 12,000 patients in the US annually? Mustang is developing MB-109, a CAR-T cell therapy and oncolytic virus combination, to potentially treat recurrent GBM more effectively.
1
381
Learn more about the rare diseases that Mustang Bio is developing treatments for at MustangBio.com and check out the NORD site to see how you can #ShowYourStripes in support of the 300 million people with rare diseases and disabilities worldwide.
150